{
    "clinical_study": {
        "@rank": "56860", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Other", 
                "description": "Standard of Care: Moist Wound Therapy"
            }, 
            {
                "arm_group_label": "EpiFix", 
                "arm_group_type": "Experimental", 
                "description": "Weekly application of EpiFix and standard of care"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the EpiFix human amniotic membrane is\n      effective in the treatment of diabetic foot ulcers."
        }, 
        "brief_title": "Trial of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers", 
        "condition": "Diabetic Foot Ulcer", 
        "condition_browse": {
            "mesh_term": [
                "Ulcer", 
                "Foot Ulcer", 
                "Diabetic Foot"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female age 18 or older\n\n          -  Informed consent must be obtained\n\n          -  Patient's ulcer must be diabetic in origin with a size ranging from 1 to 25 cm2.\n\n        Debridement will be done prior to randomization.\n\n          -  Wounds should be diabetic foot ulcers located on the plantar surface of the foot.\n\n          -  Subject's informed consent for participating in this study, must be obtained prior to\n             proceeding with sharp debridement.\n\n          -  Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes\n             mellitus per ADA).\n\n          -  Ulcer must be present for a minimum of four weeks, with documented failure of prior\n             treatment to heal the wound (< 20% wound area reduction for two consecutive weeks\n             immediately prior to enrollment when treated with standard protocol of care).\n\n          -  Patient's ulcer must exhibit no clinical signs of infection.\n\n          -  Patient is of legal consenting age.\n\n          -  Patient is willing to provide informed consent and is willing to participate in all\n             procedures and follow up evaluations necessary to complete the study.\n\n          -  Serum Creatine less then 3.0mg/dl\n\n          -  HbA1c less than 12%\n\n          -  Patient has adequate circulation to the affected extremity, as demonstrated by one of\n             the following within the past 60 days:\n\n               -  Dorsum transcutaneous oxygen test (TcPO2) with results \u2265 30mmHg, OR\n\n               -  ABIs with results of \u22650.7 and \u22641.2, OR\n\n               -  Doppler arterial waveforms, which are triphasic or biphasic at the ankle of\n                  affected leg\n\n        Exclusion Criteria:\n\n          -  Patients presenting with an ulcer probing to bone (UT Grade IIIA-D). A positive\n             probe-to-bone will be confirmed when bone or joint can be felt with a sterile,\n             ophthalmological probe.\n\n          -  Patients whose index diabetic foot ulcer is smaller than 1 cm2 or greater than 25cm2.\n             Or multiple wounds on the same foot where other wounds are within 5 cm of the wound\n             under care.\n\n          -  Patients considered not in reasonable metabolic control, confirmed by an HbA1c\n             greater  than 12% within previous 90 days,\n\n          -  Patients whose serum creatinine levels are 3.0mg/dl or greater.\n\n          -  Patients with a known history of poor compliance with medical treatments.\n\n          -  Patients who have been previously randomized into this study, or are presently\n             participating in another clinical trial\n\n          -  Patients who are currently receiving radiation therapy or chemotherapy.\n\n          -  Patients with known or suspected local skin malignancy to the index diabetic ulcer.\n\n          -  Patients diagnosed with autoimmune connective tissues diseases.\n\n          -  Nonrevascularizable surgical sites\n\n          -  Active infection at site\n\n          -  Any pathology that would limit the blood supply and compromise healing;\n\n          -  Patients that have received a biomedical or topical growth factor for their wound\n             within the previous 30 days\n\n          -  Patient who are pregnant or breast feeding\n\n          -  Patient who are taking medications that are considered immune system modulator which\n             could affect graft incorporation.\n\n          -  Allergy to Gentamycin or Streptomycin\n\n          -  Active Charcot deformity or major structural abnormalities of the foot.\n\n          -  Wounds that are not on the plantar surface of the foot.\n\n          -  Wounds that are greater than one year in duration without intermittent closure."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01693133", 
            "org_study_id": "EFDFU003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Control", 
                "description": "Standard of Care: Moist Wound Therapy", 
                "intervention_name": "Standard of Care: Moist Wound Therapy", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "EpiFix", 
                "description": "Weekly application of EpiFix and Standard of Care", 
                "intervention_name": "EpiFix", 
                "intervention_type": "Other"
            }
        ], 
        "lastchanged_date": "December 4, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Framingham", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01702"
                }, 
                "name": "MetroWest Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Pasquale Cancelliere, DPM", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Donald Adams, DPM", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "James Parlon, DPM", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-Center, Prospective, Randomized, Controlled, Comparative Parallel Study of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers", 
        "overall_contact": {
            "email": "Pasquale.Cancelliere@MWMC.com", 
            "last_name": "Pasquale Cancelliere, DPM", 
            "phone": "(508) 872-9288"
        }, 
        "overall_official": {
            "affiliation": "Metro West Medical Center", 
            "last_name": "Pasquale Cancelliere, DPM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_outcome": {
            "measure": "The proportion of ulcers achieving 50% wound area reduction in the EpiFix group versus the Control group", 
            "time_frame": "4 Week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01693133"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Time to complete closure for both groups", 
            "time_frame": "Up to 6 Weeks"
        }, 
        "source": "MiMedx Group, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MiMedx Group, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}